AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36942060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 32640882 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial 12-lead electrocardiograms once daily for five days
Number of subjects: 826
Study 32640882 — intervention group
Group type: COMPARATOR
Intervention: 24‐h Holter monitoring
Number of subjects: 826
Study 33491027 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (VIVIFRAIL) for 12 weeks, minimum 3 weekly sessions of 45–60 minutes
Number of subjects: 61
Study 33491027 — intervention group
Group type: COMPARATOR
Intervention: Control group received physical daily training (yoga, cardio-dance or tai chi)
Number of subjects: 61
Study 32093882 — intervention group
Group type: EXPERIMENTAL
Intervention: Underbleb subtenonian anesthesia (USA)
Number of subjects: 97
Study 32093882 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar anesthesia (PA)
Number of subjects: 97
Study 32930513 — intervention group
Group type: EXPERIMENTAL
Intervention: Current mental ill-health risk profile (n = 119)
Number of subjects: 355
Study 32930513 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievable mental ill-health risk profile (n = 118)
Number of subjects: 355
Study 32930513 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 118)
Number of subjects: 355
Study 32480417 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF:Ag and VWF:GPIbM levels postoperatively
Number of subjects: 59
Study 32480417 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood type non-O or medium risk surgery
Number of subjects: 59
Study 32480417 — intervention group
Group type: EXPERIMENTAL
Intervention: VWFpp/VWF:Ag ratio immediately after surgery
Number of subjects: 59
Study 32480417 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest VWF:Ag quartile (0.43-0.92 IU/mL)
Number of subjects: 59
Study 32480417 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF levels
Number of subjects: 59
Study 35078765 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC-F (fosfomycin at 100 mg/kg two times per day for up to 7 days)
Number of subjects: 120
Study 35078765 — intervention group
Group type: COMPARATOR
Intervention: SOC (standard-of-care antibiotics)
Number of subjects: 120
Study 33482769 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously once every 4 weeks, with loading doses on study days 8 and 15
Number of subjects: 526
Study 34148781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis preparations (most commonly cannabidiol)
Number of subjects: 312
Study 34148781 — intervention group
Group type: COMPARATOR
Intervention: No cannabis use (control group)
Number of subjects: 312
Study 32243402 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine combined with western medicine
Number of subjects: 60
Study 32243402 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine treatment
Number of subjects: 60
Study 35622826 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 2400
Study 35622826 — intervention group
Group type: COMPARATOR
Intervention: Standard perioperative management
Number of subjects: 2400
Study 34046496 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraCal
Number of subjects: 30
Study 34046496 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 30
Study 34046496 — intervention group
Group type: COMPARATOR
Intervention: MTA
Number of subjects: 30
Study 32323046 — intervention group
Group type: EXPERIMENTAL
Intervention: SOLACE (8-week psychosocial stigma protection intervention)
Number of subjects: 17
Study 32323046 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 17
Study 35435321 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate moisturizing after washing
Number of subjects: 60
Study 35435321 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed moisturizing at 30 minutes after washing
Number of subjects: 60
Study 35435321 — intervention group
Group type: COMPARATOR
Intervention: Non‐moisturized skin
Number of subjects: 60
Study 35435321 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate moisturizing
Number of subjects: 60
Study 35435321 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed moisturizing
Number of subjects: 60
Study 32074247 — intervention group
Group type: EXPERIMENTAL
Intervention: COAPT study
Number of subjects: 0
Study 32074247 — intervention group
Group type: EXPERIMENTAL
Intervention: MITRA-FR study
Number of subjects: 0
Study 33929598 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-White patients
Number of subjects: 5380
Study 33929598 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged > 65
Number of subjects: 5380
Study 33929598 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 5380
Study 34838412 — intervention group
Group type: EXPERIMENTAL
Intervention: DiaLife education program for relatives of adults with diabetes
Number of subjects: 179
Study 34838412 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list condition)
Number of subjects: 179
Study 34838412 — intervention group
Group type: EXPERIMENTAL
Intervention: DiaLife education program for relatives of people with type 2 diabetes
Number of subjects: 179
Study 33010470 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐paced, interactive, multimedia module (SPM)
Number of subjects: 127
Study 33010470 — intervention group
Group type: COMPARATOR
Intervention: Traditional didactic session (TDS)
Number of subjects: 127
Study 33010470 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SPM and TDS)
Number of subjects: 127
Study 32441241 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine plus cystine (Met+Cys) intake at 313 mg/day for P1 (2 to 6 weeks)
Number of subjects: 1448
Study 32441241 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine plus cystine (Met+Cys) intake at 381 mg/day for P2 (8 to 12 weeks)
Number of subjects: 1448
Study 32441241 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine plus cystine (Met+Cys) intake at 318 mg/day for P3 (14 to 18 weeks)
Number of subjects: 1448
Study 32441241 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine plus cystine (Met+Cys) requirements for WG: 20 mg/g for P1, 22 mg/g for P2, 27 mg/g for P3
Number of subjects: 1448
Study 32441241 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine plus cystine (Met+Cys) requirements for maintenance: 214 mg/kgBW0.75 for P1, 53 mg/kgBW0.75 for P2, 30 mg/kgBW0.75 for P3
Number of subjects: 1448
Study 35866585 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (three to four times per week for 25-40 minutes at 50%-70% of heart rate reserve)
Number of subjects: 0
Study 35866585 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34803547 — intervention group
Group type: EXPERIMENTAL
Intervention: Situated simulation-based (SSB) program with standardized child patients
Number of subjects: 62
Study 34803547 — intervention group
Group type: COMPARATOR
Intervention: Video training (control group)
Number of subjects: 62
Study 32867994 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lead nitrate at 3.20 mg/kg
Number of subjects: 512
Study 32867994 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lead nitrate at 33.20 mg/kg
Number of subjects: 512
Study 32867994 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lead nitrate at 63.20 mg/kg
Number of subjects: 512
Study 32867994 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lead nitrate at 93.20 mg/kg
Number of subjects: 512
Study 36008074 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) device, 8-week home-based intervention, footplate stimulation for 30 minutes daily and quadriceps stimulation for 20 minutes, five times a week.
Number of subjects: 193
Study 36008074 — intervention group
Group type: COMPARATOR
Intervention: Sham device, 8-week home-based intervention.
Number of subjects: 193
Study 36008074 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES device
Number of subjects: 193
Study 36008074 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 193
Study 34524395 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-weight polypropylene mesh
Number of subjects: 350
Study 34524395 — intervention group
Group type: COMPARATOR
Intervention: Medium-weight polypropylene mesh
Number of subjects: 350
Study 33728637 — intervention group
Group type: EXPERIMENTAL
Intervention: New approach to reducing substance use (details not specified)
Number of subjects: 0
Study 36255569 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (2 mg and 4 mg extended)
Number of subjects: 341
Study 36255569 — intervention group
Group type: EXPERIMENTAL
Intervention: All baricitinib doses
Number of subjects: 341
Study 36255569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 36141644 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 53
Study 36141644 — intervention group
Group type: COMPARATOR
Intervention: Meat-rich diet
Number of subjects: 53
Study 36141644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 53
Study 33243667 — intervention group
Group type: EXPERIMENTAL
Intervention: Scandinavian Obesity Surgery Registry (SOReg) data collection
Number of subjects: 34628
Study 33243667 — intervention group
Group type: EXPERIMENTAL
Intervention: Reabstracted data from SOReg
Number of subjects: 34628
Study 33243667 — intervention group
Group type: EXPERIMENTAL
Intervention: Variables studied in SOReg
Number of subjects: 34628
Study 33243667 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory variables in SOReg
Number of subjects: 34628
Study 35708631 — intervention group
Group type: EXPERIMENTAL
Intervention: KGR-BG1 (1500 mg oral dose containing 1000 mg active component, twice daily for 6 weeks)
Number of subjects: 180
Study 35708631 — intervention group
Group type: COMPARATOR
Intervention: Korean Red Ginseng Extract (1500 mg oral dose containing 1000 mg active component, twice daily for 6 weeks)
Number of subjects: 180
Study 35708631 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1500 mg oral dose, twice daily for 6 weeks)
Number of subjects: 180
Study 32051147 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Sinemet (levodopa plus carbidopa) for 2 weeks
Number of subjects: 0
Study 32051147 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Sinemet (levodopa plus carbidopa) for 2 weeks
Number of subjects: 0
Study 32051147 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no diabetes)
Number of subjects: 0
Study 32564076 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 10 mg/kg daily for 12 months
Number of subjects: 300
Study 32564076 — intervention group
Group type: COMPARATOR
Intervention: No Isoniazid (no INH)
Number of subjects: 300
Study 32295423 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial events (critical limb ischemia or stroke)
Number of subjects: 1082
Study 32295423 — intervention group
Group type: COMPARATOR
Intervention: Age- and sex-matched controls
Number of subjects: 1082
Study 35176678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) twice weekly
Number of subjects: 200
Study 35176678 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT) once weekly
Number of subjects: 200
Study 35176678 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT) twice weekly
Number of subjects: 200
Study 35176678 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT) once weekly
Number of subjects: 200
Study 35176678 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT skills
Number of subjects: 200
Study 35176678 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in depression
Number of subjects: 200
Study 36448389 — intervention group
Group type: EXPERIMENTAL
Intervention: PVRU of 200 ml
Number of subjects: 0
Study 36448389 — intervention group
Group type: COMPARATOR
Intervention: PVRU of 300 ml
Number of subjects: 0
Study 33725616 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy (HT)
Number of subjects: 152
Study 33725616 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 152
Study 33377369 — intervention group
Group type: EXPERIMENTAL
Intervention: Camellia seed oil (CSO)
Number of subjects: 0
Study 33377369 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 0
Study 33377369 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil
Number of subjects: 0
Study 35445883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (tailored clinic staff training on postpartum depression, awareness raising, and social support)
Number of subjects: 332
Study 35445883 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 332
Study 35445883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (high PPD awareness)
Number of subjects: 332
Study 35445883 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (high social support)
Number of subjects: 332
Study 33727268 — intervention group
Group type: EXPERIMENTAL
Intervention: Local consolidation radiation therapy (RT) and standard maintenance therapy
Number of subjects: 190
Study 33727268 — intervention group
Group type: COMPARATOR
Intervention: Standard maintenance therapy
Number of subjects: 190
Study 32715427 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence and precision mental health approaches
Number of subjects: 0
Study 32715427 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 34134684 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg twice daily (BID)
Number of subjects: 1686
Study 34134684 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily (QD)
Number of subjects: 1686
Study 34134684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1686
Study 32761610 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted magnesium concentration (1 SD higher, SD: 0.08 mmol/L)
Number of subjects: 228951
Study 32761610 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted phosphorus concentration (1 SD higher, SD: 0.5 mg/dL)
Number of subjects: 228951
Study 34501569 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 233
Study 34501569 — intervention group
Group type: COMPARATOR
Intervention: Gain-framed message
Number of subjects: 233
Study 32422113 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold 532 nm Diode Micropulse Laser (SML)
Number of subjects: 60
Study 32422113 — intervention group
Group type: COMPARATOR
Intervention: Conventional Laser Photocoagulation (CLP)
Number of subjects: 60
Study 36228641 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 1·2 mg followed by 0·6 mg 2 h later and then 0·6 mg twice daily for 28 days
Number of subjects: 2749
Study 36228641 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2·5 mg twice daily plus aspirin 100 mg once daily for 28 days
Number of subjects: 2749
Study 36228641 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care) for colchicine
Number of subjects: 2749
Study 36228641 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care) for rivaroxaban and aspirin
Number of subjects: 2749
Study 36228641 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 2749
Study 36228641 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban and aspirin
Number of subjects: 2749
Study 33245168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcosine (2 g daily)
Number of subjects: 57
Study 33245168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 35091440 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 4047
Study 34118178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobocertinib (TAK-788) 20-160 mg
Number of subjects: 69
Study 34118178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobocertinib (120/160 mg) under fasted or low-fat meal conditions
Number of subjects: 69
Study 34118178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobocertinib 160 mg in 1 of 2 capsule products
Number of subjects: 69
Study 32151367 — intervention group
Group type: EXPERIMENTAL
Intervention: Naldemedine 0.2 mg once daily for 2 weeks (COMPOSE-4)
Number of subjects: 324
Study 32151367 — intervention group
Group type: EXPERIMENTAL
Intervention: Naldemedine 0.2 mg once daily for 12 weeks (COMPOSE-5)
Number of subjects: 324
Study 32151367 — intervention group
Group type: COMPARATOR
Intervention: Naldemedine 0.2 mg
Number of subjects: 324
Study 34363708 — intervention group
Group type: COMPARATOR
Intervention: Erenumab 140 mg
Number of subjects: 375
Study 34363708 — intervention group
Group type: COMPARATOR
Intervention: Erenumab 70 mg
Number of subjects: 375
Study 33706345 — intervention group
Group type: EXPERIMENTAL
Intervention: Any breastfeeding
Number of subjects: 772
Study 33706345 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional month of breastfeeding
Number of subjects: 772
Study 33706345 — intervention group
Group type: COMPARATOR
Intervention: No breastfeeding
Number of subjects: 772
Study 34508607 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (300,000 IU cholecalciferol followed by 1400 IU cholecalciferol + 500 mg of calcium daily for 150 days)
Number of subjects: 307
Study 34508607 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=156)
Number of subjects: 307
Study 32428912 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% Retinol Serum
Number of subjects: 37
Study 32428912 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Retinol Serum
Number of subjects: 37
Study 32428912 — intervention group
Group type: COMPARATOR
Intervention: Study Vehicle (Control)
Number of subjects: 37
Study 35421407 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentapen (1.8 mL/162 sec, ramp-up setting)
Number of subjects: 130
Study 35421407 — intervention group
Group type: COMPARATOR
Intervention: Traditional syringe (1.8 mL/60 sec)
Number of subjects: 130
Study 35421407 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentapen
Number of subjects: 130
Study 33547257 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR)
Number of subjects: 25
Study 33547257 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study 32847902 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus access to My Journey 3 on their own Smartphone
Number of subjects: 40
Study 32847902 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual from EIP services (TAU)
Number of subjects: 40
Study 35621117 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing blood donor eligibility questionnaire
Number of subjects: 903
Study 35621117 — intervention group
Group type: COMPARATOR
Intervention: Modified donor questionnaire that repositioned the MSM question among neutral questions
Number of subjects: 903
Study 33247448 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 nM EBR
Number of subjects: 0
Study 33247448 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 nM EBR
Number of subjects: 0
Study 32002769 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 736
Study 32002769 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 736
Study 32002769 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban and Warfarin
Number of subjects: 736
Study 36413125 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray after an overnight fast
Number of subjects: 20
Study 36413125 — intervention group
Group type: COMPARATOR
Intervention: Diazepam nasal spray after a standardized high-fat, high-calorie breakfast
Number of subjects: 20
Study 36413125 — intervention group
Group type: COMPARATOR
Intervention: Fasted conditions
Number of subjects: 20
Study 36413125 — intervention group
Group type: COMPARATOR
Intervention: Fed conditions
Number of subjects: 20
Study 33592892 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified seton cutting technique
Number of subjects: 204
Study 33592892 — intervention group
Group type: COMPARATOR
Intervention: Cutting seton technique
Number of subjects: 204
Study 34125734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat (ITT) analysis
Number of subjects: 0
Study 34125734 — intervention group
Group type: EXPERIMENTAL
Intervention: Average treatment effect (ATE) with no assumptions
Number of subjects: 0
Study 34125734 — intervention group
Group type: EXPERIMENTAL
Intervention: Average treatment effect (ATE) with minimum assumptions
Number of subjects: 0
Study 34125734 — intervention group
Group type: EXPERIMENTAL
Intervention: Complier average treatment effect (complier ATE)
Number of subjects: 0
Study 33387498 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) with prescribed doses ranging from 24–60 Gy administered in three to eight fractions.
Number of subjects: 1422
Study 33387498 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR)
Number of subjects: 1422
Study 34197323 — intervention group
Group type: EXPERIMENTAL
Intervention: Image reconstruction network with residual block structure and perceptual loss
Number of subjects: 0
Study 34197323 — intervention group
Group type: EXPERIMENTAL
Intervention: Image reconstruction network with randomization layers
Number of subjects: 0
Study 34197323 — intervention group
Group type: EXPERIMENTAL
Intervention: Image reconstruction network
Number of subjects: 0
Study 32134984 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical crowdfunding campaigns organized by individuals
Number of subjects: 637
Study 32134984 — intervention group
Group type: EXPERIMENTAL
Intervention: Campaign characteristics under users' control (photos, videos, updates)
Number of subjects: 637
Study 35428627 — intervention group
Group type: EXPERIMENTAL
Intervention: IPRP + eVIS
Number of subjects: 400
Study 35428627 — intervention group
Group type: COMPARATOR
Intervention: IPRP only
Number of subjects: 400
Study 33539760 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV clinic-based buprenorphine plus naloxone treatment
Number of subjects: 281
Study 33539760 — intervention group
Group type: COMPARATOR
Intervention: Referral for methadone maintenance therapy
Number of subjects: 281
Study 35879007 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved maternity waiting homes (MWH) model
Number of subjects: 158